The company's financial position is weakening, with total assets contracting from $15.2M in 2024Q1 to $6.9M in 2026Q1, reflecting the ongoing depletion of capital to cover operational deficits.
Nutriband Inc. (NTRB) balance sheet — 11-year assets, liabilities & shareholders' equity history
| Metric | TTM | Jan'26 | Jan'25 | Jan'24 | Jan'23 | Jan'22 | Jan'21 | Jan'20 | Jan'19 | Jan'18 | Jan'17 | Jan'16 |
|---|
| Total Current Assets | 3.82M | 4.99M | 4.79M | 1.02M | 2.69M | 5.47M | 314.19K | 43.18K | 590.47K | 164.9K | 37.73K | 330 |
| Cash & Short-Term Investments | 3.42M | 4.57M | 4.31M | 492.94K | 1.99M | 4.89M | 151.99K | 10.18K | 474.65K | 0 | 27.12K | 100 |
| Cash Only | 3.42M | 4.57M | 4.31M | 492.94K | 1.99M | 4.89M | 151.99K | 10.18K | 474.65K | 0 | 27.12K | 100 |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 23.59K | 118.4K | 73.85K | 148.65K | 113.05K | 71.38K | 109.35K | 12.83K | 13.09K | 263 | 229 | 230 |
| Days Sales Outstanding | 16.48 | 21.22 | 12.6 | 26.02 | 19.84 | 18.32 | 42.29 | 12.64 | 19.48 | - | - | - |
| Inventory | 170.73K | 117.99K | 212.04K | 168.6K | 229.34K | 131.65K | 52.85K | 0 | 0 | 4.13K | 8.05K | 0 |
| Days Inventory Outstanding | 44.99 | 28.45 | 53.75 | 50.31 | 62.98 | 52.35 | 33.12 | 0 | - | - | - | - |
| Other Current Assets | 0 | 0 | -546 | 0 | 0 | 0 | 0 | 0 | 102.72K | 0 | 0 | 0 |
| Total Non-Current Assets | 2.47M | 2.56M | 2.68M | 6.5M | 6.76M | 7.27M | 9.61M | 2.15M | 2.22M | 0 | 0 | 0 |
| Property, Plant & Equipment | 584.09K | 639.25K | 695.06K | 806.3K | 960.49K | 998.34K | 1.08M | 120.64K | 146.15K | 0 | 0 | 0 |
| Fixed Asset Turnover | 2.58x | 3.19x | 3.08x | 2.59x | 2.17x | 1.42x | 0.88x | 3.07x | 1.68x | - | - | - |
| Goodwill | 1.72M | 1.72M | 1.72M | 5.02M | 5.02M | 5.35M | 7.53M | 1.72M | 1.72M | 0 | 0 | 0 |
| Intangible Assets | 170.09K | 200.43K | 261.09K | 667.28K | 780.43K | 926.91K | 1.01M | 314.7K | 351.77K | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | -63 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 6.29M | 7.55M | 7.47M | 7.52M | 9.46M | 12.74M | 9.93M | 2.2M | 2.81M | 164.9K | 37.73K | 330 |
| Asset Turnover | 0.22x | 0.27x | 0.29x | 0.28x | 0.22x | 0.11x | 0.10x | 0.17x | 0.09x | - | - | - |
| Asset Growth % | -57.96% | 1.04% | -0.63% | -20.51% | -25.77% | 28.33% | 351.71% | -21.72% | 1602.63% | 337.08% | 11332.42% | - |
| Total Current Liabilities | 907.05K | 784.28K | 982.85K | 999.09K | 748.61K | 779.26K | 2.57M | 2.02M | 403.01K | 43.39K | 14.62K | 11.11K |
| Accounts Payable | 644.52K | 502.65K | 698.82K | 680.13K | 0 | 0 | 0 | 771.93K | 291.78K | 12.34K | 4.15K | 1.2K |
| Days Payables Outstanding | 155.6 | 121.22 | 177.13 | 202.95 | - | - | - | 513.11 | 369.41 | - | - | - |
| Short-Term Debt | 162.41K | 161.32K | 128.14K | 127.18K | 19.74K | 14.12K | 1.52M | 311.57K | 40K | 31.05K | 10.47K | 9.91K |
| Deferred Revenue (Current) | 257.8K | 120.3K | 155.88K | 157.5K | 162.9K | 106.27K | 86.85K | 0 | 71.22K | -43.39K | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 534.68K | 639.54K | 940.61K | 928.77K | 0 | 0 | 0 | 0 |
| Current Ratio | 4.21x | 6.36x | 4.88x | 1.02x | 3.60x | 7.01x | 0.12x | 0.02x | 1.47x | 3.80x | 2.58x | 0.03x |
| Quick Ratio | 4.02x | 6.21x | 4.66x | 0.85x | 3.29x | 6.84x | 0.10x | 0.02x | 1.47x | 3.71x | 2.03x | 0.03x |
| Cash Conversion Cycle | -94.12 | -71.55 | -110.79 | -126.62 | - | - | - | -500.48 | - | - | - | - |
| Total Non-Current Liabilities | 57.31K | 84.17K | 58.2K | 79.83K | 134.77K | 101.12K | 246.87K | 0 | 0 | 0 | 0 | 686 |
| Long-Term Debt | 32.21K | 35.86K | 58.2K | 79.83K | 100.5K | 101.12K | 150.06K | 0 | 0 | 0 | 0 | 686 |
| Capital Lease Obligations | 40.35K | 48.3K | 0 | 0 | 34.28K | 0 | 96.8K | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 25.1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 964.36K | 868.45K | 1.04M | 1.08M | 883.39K | 880.38K | 2.82M | 2.02M | 403.01K | 43.39K | 14.62K | 11.8K |
| Total Debt | 194.62K | 245.49K | 186.35K | 241.28K | 185.81K | 134.57K | 1.79M | 321.62K | 40K | 31.05K | 10.47K | 10.6K |
| Net Debt | -3.23M | -4.33M | -4.13M | -251.66K | -1.8M | -4.76M | 1.64M | 311.44K | -434.65K | 31.05K | -16.66K | 10.5K |
| Debt / Equity | 0.04x | 0.04x | 0.03x | 0.04x | 0.02x | 0.01x | 0.25x | 1.83x | 0.02x | 0.26x | 0.45x | - |
| Debt / EBITDA | -0.03x | - | - | - | - | - | - | - | - | - | - | 2.41x |
| Net Debt / EBITDA | 0.47x | - | - | - | - | - | - | - | - | - | - | 2.39x |
| Interest Coverage | -655.59x | -369.11x | -488.67x | -71.35x | -539.89x | -51.15x | -9.45x | -36.07x | - | - | - | - |
| Total Equity | 5.33M | 6.68M | 6.43M | 6.44M | 8.57M | 11.86M | 7.11M | 175.43K | 2.4M | 121.51K | 23.11K | -11.47K |
| Equity Growth % | -48.78% | 3.9% | -0.14% | -24.9% | -27.71% | 66.75% | 3953.94% | -92.7% | 1878.97% | 425.8% | 301.47% | - |
| Book Value per Share | 0.44 | 0.57 | 0.61 | 0.81 | 1.01 | 1.49 | 1.06 | 0.03 | 0.39 | 0.02 | 0.00 | -0.00 |
| Total Shareholders' Equity | 5.33M | 6.68M | 6.43M | 6.44M | 8.57M | 11.86M | 7.11M | 175.43K | 2.4M | 121.51K | 23.11K | -11.47K |
| Common Stock | 12.16K | 12.16K | 11.07K | 8.86K | 7.83K | 9.15K | 6.26K | 5.44K | 21.7K | 20.88K | 15.57K | 21.88K |
| Retained Earnings | -48.81M | -46.69M | -38.46M | -27.98M | -22.49M | -18.01M | -11.84M | -8.9M | -6.18M | -2.85M | -177.46K | -26.2K |
| Treasury Stock | -87.91K | -86.85K | -149K | -32.64K | -32.64K | -104.47K | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -304 | -304 | -304 | -304 | -304 | -304 | -304 | -304 | -52 | -446 | 1.71K | 1.64K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying NTRB stock.
As of 2025, Nutriband Inc. (NTRB) had total assets of $7.5M including $5.0M in current assets.
Nutriband Inc. (NTRB) carries total debt of $0.2M, offset by $4.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Nutriband Inc. (NTRB) has total shareholders' equity (book value) of $6.7M ($0.57 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Nutriband Inc. (NTRB) reported a current ratio of 6.36x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Liquidity and clinical binary
Metrics are mathematically derived from official filings.
Asset Base Contraction Signals Instability
According to the provided quarterly data, Nutriband's total assets have declined from a peak of $15.2M in 2024Q1 to $6.9M in 2026Q1, reflecting a consistent erosion of the balance sheet as the company consumes capital to fund its ongoing clinical development and operational requirements.
The downward trend in total assets suggests that the company is struggling to replenish its resource base through internal operations or external financing. This contraction warrants close monitoring, as it limits the company's financial flexibility and ability to absorb potential regulatory or clinical setbacks.
Cash Runway Remains Critically Thin
As reported in financial statements, Nutriband's cash position of $4.0M in 2026Q1, while improved from the 2023Q4 low of $492.9K, remains insufficient to support long-term R&D burn rates, leaving the firm with a narrow buffer against unexpected operational or regulatory delays in its AVERSA program.
While the current ratio of 5.26 appears healthy on the surface, it is heavily influenced by the composition of current assets rather than immediate cash availability. Investors should interpret this liquidity profile as precarious, given the company's history of negative operating cash flows and the high costs associated with clinical-stage biotechnology.
Intangible Asset Impairment Risks Loom
Based on the balance sheet figures, goodwill has decreased from $5.0M in 2024Q3 to $1.7M in 2026Q1, which may indicate management's recognition of diminished value in previously acquired assets or a strategic shift in the valuation of its core intellectual property portfolio.
The reduction in goodwill suggests that the carrying value of past acquisitions is being reassessed, which may imply that the expected synergies or commercial potential of those assets have not materialized as anticipated. This trend warrants further investigation into whether additional impairments could impact future equity levels.
Equity Erosion Through Persistent Losses
As indicated by the company's financial disclosures, retained earnings have deteriorated to -$47.9M in 2026Q1, a clear reflection of the cumulative impact of sustained operating losses that continue to erode the company's book value and overall equity base over the observed ten-quarter period.
The consistent decline in retained earnings highlights the company's reliance on external capital to offset its operational deficits. This pattern suggests that shareholders are bearing the brunt of the company's development-stage costs, and future equity quality remains highly sensitive to the success of the AVERSA clinical pathway.